Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Aug 14;99(8):1679–1684. doi: 10.1111/j.1349-7006.2008.00857.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2008 Japanese Cancer Association

PMC Copyright notice

Lipopolysaccharide (LPS)‐induced inflammatory change in vivo. (a) Cell density in bronchoalveolar lavage (BAL) fluid from mice with/without gefitinib pretreatment, 6 days after intratracheal LPS instillation. (b) Infiltration of inflammatory cells 3 days after LPS instillation in the lungs of mice treated with gefitinib only (left), with LPS only (middle), or with gefitinib and LPS (right). (c) Tumor necrosis factor (TNF)‐α enzyme‐linked immunosorbent assay was performed on mouse BAL fluid 8, 24 and 72 h after the intratracheal LPS instillation (n = 6). () mice receiving LPS only; () mice receiving gefitinib and LPS. Data presents means ± standard error (SE) in five mice. *P < 0.05.

Inline graphic — Lipopolysaccharide (LPS)‐induced inflammatory change in vivo. (a) Cell density in bronchoalveolar lavage (BAL) fluid from mice with/without gefitinib pretreatment, 6 days after intratracheal LPS instillation. (b) Infiltration of inflammatory cells 3 days after LPS instillation in the lungs of mice treated with gefitinib only (left), with LPS only (middle), or with gefitinib and LPS (right). (c) Tumor necrosis factor (TNF)‐α enzyme‐linked immunosorbent assay was performed on mouse BAL fluid 8, 24 and 72 h after the intratracheal LPS instillation (n = 6). () mice receiving LPS only; () mice receiving gefitinib and LPS. Data presents means ± standard error (SE) in five mice. *P < 0.05.